Literature DB >> 21658937

Management of metastatic castration-resistant prostate cancer after first-line docetaxel.

J A Harrington1, R J Jones.   

Abstract

Although chemotherapy, based on docetaxel, is now established in the management of metastatic castration-resistant prostate cancer (mCRPC), until recently, there has been no treatment licensed for use in the second line in men whose disease progresses during or after docetaxel therapy. This article reviews the classes of agents that have shown potential in this setting, notably chemotherapy drugs, hormonal therapies, immunotherapies, anti-angiogenic drugs, and clusterin-targeted therapy.
Copyright © 2011 Elsevier Ltd. All rights reserved.

Entities:  

Mesh：

Substances：

Year:  2011        PMID： 21658937     DOI： 10.1016/j.ejca.2011.04.036

Source DB:  PubMed          Journal:  Eur J Cancer        ISSN： 0959-8049            Impact factor:   9.162


  6 in total

1.  N-terminal targeting of androgen receptor variant enhances response of castration resistant prostate cancer to taxane chemotherapy.

Authors:  Sarah K Martin; Carmen A Banuelos; Marianne D Sadar; Natasha Kyprianou
Journal:  Mol Oncol       Date:  2014-11-15       Impact factor: 6.603

2.  Multinucleation and Mesenchymal-to-Epithelial Transition Alleviate Resistance to Combined Cabazitaxel and Antiandrogen Therapy in Advanced Prostate Cancer.

Authors:  Sarah K Martin; Hong Pu; Justin C Penticuff; Zheng Cao; Craig Horbinski; Natasha Kyprianou
Journal:  Cancer Res       Date:  2015-12-08       Impact factor: 12.701

3.  Androgen receptor negatively regulates mitotic checkpoint signaling to induce docetaxel resistance in castration-resistant prostate cancer.

Authors:  Amanda Pilling; Sahn-Ho Kim; Clara Hwang
Journal:  Prostate       Date:  2021-10-21       Impact factor: 4.012

Review 4.  Recent Advances in Nanomedicine for the Diagnosis and Treatment of Prostate Cancer Bone Metastasis.

Authors:  Daniel E Hagaman; Jossana A Damasco; Joy Vanessa D Perez; Raniv D Rojo; Marites P Melancon
Journal:  Molecules       Date:  2021-01-13       Impact factor: 4.411

5.  Androgen receptor as a driver of therapeutic resistance in advanced prostate cancer.

Authors:  Barbara Kahn; Joanne Collazo; Natasha Kyprianou
Journal:  Int J Biol Sci       Date:  2014-06-01       Impact factor: 6.580

Review 6.  Impact of taxanes on androgen receptor signaling.

Authors:  Shanshan Bai; Bryan Y Zhang; Yan Dong
Journal:  Asian J Androl       Date:  2019 May-Jun       Impact factor: 3.285
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.